GlassScriptPhysician profile
William Blair Townsend
NPI 1619231321
$7,979.27
in general payments reported to CMS, 2019-2025
36 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $2,593 · 2023: $1,909 · 2024: $1,512 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,783 · Education: $200 · Travel and Lodging: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.69 |
| Education | $199.98 |
| Travel and Lodging | $134.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $967.73 | 2022-2025 | General - Erectile Dysfunction, Lithovue, Axonics |
| Intuitive Surgical, INC. | $897.13 | 2022-2023 | Da Vinci Sp |
| Dendreon Pharmaceuticals LLC | $766.62 | 2022-2025 | Provenge |
| Astellas Pharma US INC | $625.04 | 2022-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $443.50 | 2021-2024 | Aquabeam Robotic System, Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $398.87 | 2023-2025 | |
| Janssen Biotech, INC. | $381.24 | 2022-2025 | Erleada |
| Medtronic, INC. | $359.59 | 2022-2024 | Interstim |
| Sun Pharmaceutical Industries INC. | $306.42 | 2022-2025 | Yonsa |
| Abbvie INC. | $304.82 | 2022-2025 | Lupron Depot |
| Axogen | $273.49 | 2025 | |
| Pfizer INC. | $273.02 | 2022-2025 | |
| Blue Earth Diagnostics | $180.70 | 2022-2025 | Posluma |
| Immunitybio, INC. | $156.75 | 2025 | |
| Urogen Pharma, INC. | $147.84 | 2021-2023 | Jelmyto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $126.85 | 2022 | |
| Calyxo, INC. | $125.52 | 2025 | Cvac Aspiration System |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Myriad Genetic Laboratories, INC. | $120.60 | 2024 | Prolaris |
| Sumitomo Pharma America, INC. | $119.19 | 2023 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $108.41 | 2024-2025 | |
| Olympus America INC. | $101.67 | 2024 | Itind System |
| Seagen INC. | $99.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $87.50 | 2022-2023 | Lynparza |
| Smith+Nephew, INC. | $60.02 | 2022-2024 | Stravix |
| Accord Healthcare, INC. | $58.65 | 2023-2024 | |
| Urovant Sciences INC | $48.40 | 2022 | |
| Teleflex LLC | $44.81 | 2024 | Urolift |
| Myovant Sciences INC. | $32.86 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $29.68 | 2022 | |
| Masimo Corporation | $18.31 | 2025 | Sedline |
| Foundation Medicine, INC. | $18.19 | 2023 | |
| Tempus Ai, INC | $17.16 | 2024 | |
| Hollister Incorporated | $14.54 | 2022 | |
| Ambu INC. | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.